Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.35 |
| ▸ | KDR | P35968 | 3/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.35 |
| ▸ | IRAK1 | P51617 | 4/20 | 0.34 |
| ▸ | WNT1 | P04628 | 3/20 | 0.34 |
| ▸ | GSK3B | P49841 | 3/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19301805 | 0.85 | PADI4 (0.39) | PADI4PIK3CDPIK3R1GRIN1GRIN2B | |
| SCHEMBL19284356 | 0.79 | PADI4 (0.41) | PADI4FGFR3FGFR1FGFR2KDR | |
| SCHEMBL19284323 | 0.75 | PADI4 (0.39) | PADI4WNT1GSK3BDYRK1A | |
| SCHEMBL19301734 | 0.64 | KDM4E (0.40) | PADI4GRIN1GRIN2B | |
| SCHEMBL19301627 | 0.64 | KDM4E (0.43) | PADI4GRIN1GRIN2B | |
| SCHEMBL31655610 | 0.62 | PIM1 (0.41) | WNT1GSK3BDYRK1A | |
| SCHEMBL17725307 | 0.62 | BRD4 (0.35) | KDRFLT3 | |
| SCHEMBL13807047 | 0.60 | LRRK2 (0.45) | PIK3CDFGFR3KDRDYRK1AFLT3 | |
| SCHEMBL28432597 | 0.60 | MKNK1 (0.49) | PIK3CDKDRFLT3 | |
| SCHEMBL22045831 | 0.60 | FLT3 (0.63) | FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | PADI4 1/4885PIK3CD 1207/4885PIK3R1 1464/4885 |
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | PADI4 1/4885PIK3CD 1207/4885PIK3R1 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.